H6Z0 logo

LakeShore Biopharma DB:H6Z0 Stock Report

Last Price

€1.66

Market Cap

€35.1m

7D

-17.0%

1Y

-73.0%

Updated

16 Mar, 2025

Data

Company Financials

LakeShore Biopharma Co., Ltd

DB:H6Z0 Stock Report

Market Cap: €35.1m

H6Z0 Stock Overview

A biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. More details

H6Z0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

LakeShore Biopharma Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for LakeShore Biopharma
Historical stock prices
Current Share PriceUS$1.66
52 Week HighUS$10.30
52 Week LowUS$0.49
Beta0.70
1 Month Change-21.70%
3 Month Change-22.43%
1 Year Change-73.01%
3 Year Changen/a
5 Year Changen/a
Change since IPO-86.10%

Recent News & Updates

Recent updates

Shareholder Returns

H6Z0DE BiotechsDE Market
7D-17.0%3.1%-0.5%
1Y-73.0%-6.0%15.5%

Return vs Industry: H6Z0 underperformed the German Biotechs industry which returned -5.8% over the past year.

Return vs Market: H6Z0 underperformed the German Market which returned 15.5% over the past year.

Price Volatility

Is H6Z0's price volatile compared to industry and market?
H6Z0 volatility
H6Z0 Average Weekly Movement23.0%
Biotechs Industry Average Movement9.3%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: H6Z0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: H6Z0's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2002758Wang Xuwww.ysbiopharm.com

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines.

LakeShore Biopharma Co., Ltd Fundamentals Summary

How do LakeShore Biopharma's earnings and revenue compare to its market cap?
H6Z0 fundamental statistics
Market cap€35.07m
Earnings (TTM)-€55.03m
Revenue (TTM)€72.80m

0.5x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
H6Z0 income statement (TTM)
RevenueCN¥573.42m
Cost of RevenueCN¥187.36m
Gross ProfitCN¥386.06m
Other ExpensesCN¥819.52m
Earnings-CN¥433.46m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-22.72
Gross Margin67.33%
Net Profit Margin-75.59%
Debt/Equity Ratio71.3%

How did H6Z0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 07:55
End of Day Share Price 2025/03/14 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LakeShore Biopharma Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hunter DiamondDiamond Equity Research LLC
Gregory AurandNOBLE Capital Markets, Inc.